Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients

NCT07717788 is registered in ClinicalTrials.gov with Alkufa university\\collage of pharmacy as lead sponsor.

NCT NCT07717788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients
Lead sponsor
Alkufa university\\collage of pharmacy
Phase
Not applicable
Overall status
Completed
Start date
February 1, 2025
Completion date
July 1, 2026
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, postmenopausal, statin therapy